Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0U3YB
|
||||
| Former ID |
DAP000913
|
||||
| Drug Name |
Masoprocol
|
||||
| Synonyms |
Actinex; Masoprocolum; NDGA; CHX 100; N 5023; TNP00263; Actinex (TN); CHX-100; Masoprocol [USAN:INN]; Masoprocolum [INN-Latin]; Meso-NDGA; Meso-Nordihydroguaiaretic acid; Nordihydroguaiaretic acid from Larrea divaricata (creosote bush); Masoprocol (USAN/INN); Nordihydroguaiaretic acid (meso-form); Meso-4,4'-(2,3-Dimethyltetramethylene)dipyrocatechol; (R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol; 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H22O4
|
||||
| InChI |
InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3
|
||||
| InChIKey |
HCZKYJDFEPMADG-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 500-38-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
12902, 70634, 519564, 799650, 855767, 3156160, 5633842, 8149857, 8152791, 10524247, 11336174, 11361413, 11364040, 11364761, 11366602, 11367323, 11369164, 11369885, 11372925, 11375485, 11377326, 11378050, 11408384, 11462385, 11494960, 14800563, 24278590, 24886494, 26759213, 29204445, 29223625, 47216857, 47291213, 47365287, 47440357, 47885496, 49748321, 50037381, 50105253, 50105254, 53789186, 56370338, 56463284, 57322317, 57390614, 57652455, 57654453, 75686389, 81093171, 85088295
|
||||
| SuperDrug ATC ID |
L01XX10
|
||||
| SuperDrug CAS ID |
cas=027686846
|
||||
| Target and Pathway | |||||
| Target(s) | Receptor protein-tyrosine kinase erbB-2 | Target Info | Modulator | [556264] | |
| KEGG Pathway | ErbB signaling pathway | ||||
| Calcium signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Focal adhesion | |||||
| Adherens junction | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| Pancreatic cancer | |||||
| Endometrial cancer | |||||
| Prostate cancer | |||||
| Bladder cancer | |||||
| Non-small cell lung cancer | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Cadherin signaling pathway | ||||
| EGF receptor signaling pathway | |||||
| PathWhiz Pathway | Phosphatidylinositol Phosphate Metabolism | ||||
| WikiPathways | DNA Damage Response (only ATM dependent) | ||||
| ErbB Signaling Pathway | |||||
| EGF/EGFR Signaling Pathway | |||||
| Focal Adhesion | |||||
| Extracellular vesicle-mediated signaling in recipient cells | |||||
| Bladder Cancer | |||||
| Signaling by ERBB2 | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Signaling Pathways in Glioblastoma | |||||
| Leptin signaling pathway | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| Semaphorin interactions | |||||
| References | |||||
| Ref 467601 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4265). | ||||
| Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.